Verve Therapeutics
VERV
VERV was delisted on the 24th of July, 2025.
101 hedge funds and large institutions have $696M invested in Verve Therapeutics in 2022 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 32 increasing their positions, 21 reducing their positions, and 17 closing their positions.
1,827% more call options, than puts
Call options by funds: $3.87M | Put options by funds: $201K
59% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 17
52% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 21
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
10% more funds holding
Funds holding: 92 → 101 (+9)
2.37% less ownership
Funds ownership: 96.02% → 93.65% (-2.4%)
35% less capital invested
Capital invested by funds: $1.06B → $696M (-$368M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$7.36M |
| 2 |
BlackRock
New York
|
+$6.59M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$6M |
| 4 |
Millennium Management
New York
|
+$5.76M |
| 5 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$5.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$31.9M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$16.8M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$15.7M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$7.08M |
| 5 |
Rafferty Asset Management
New York
|
-$4.22M |
VERV Hedge Fund Activity: Q2 2022 in Review
101 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Verve Therapeutics (VERV) for Q2 2022, worth a combined $696M — down 35% from $1.06B a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new VERV positions and 17 closed out — a net gain of 10 holders — while 32 added to existing stakes and 21 trimmed.
The largest buyer was PFM Health Sciences, adding an estimated $7.36M. The largest seller was State Street, cutting an estimated $31.9M.
- 101 institutional investors held Verve Therapeutics (VERV) as of Q2 2022, up from 92 in Q1 2022.
- Funds reported $696M of Verve Therapeutics stock for Q2 2022, down 35% quarter-over-quarter.
- 27 funds opened new Verve Therapeutics positions in Q2 2022 and 17 closed out, a net change of +10 holders.
- The largest Verve Therapeutics buyer in Q2 2022 was PFM Health Sciences, an estimated $7.36M added.
- The largest Verve Therapeutics seller in Q2 2022 was State Street, an estimated $31.9M sold.
Based on aggregated 13F filings for Q2 2022.